Hypoglycemic and hypotensive effects of 6-cyclohexyl-2'-O-methyl- adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia

Diabetes Research and Clinical Practice

Volumn 39, Issue 1, 1998, Pages 3-9

  Ishikawa, Junji ^a   Mitani, Hironobu ^a   Bandoh, Tsutomu ^a   Kimura, Masaaki ^a   Totsuka, Tetsuya ^a   Hayashi, Shigehiro ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Adenosine analogue; Free fatty acid; Glucose; Hyperglycemia; Spontaneously hypertensive rat; Triglyceride

Indexed keywords

6 CYCLOHEXYL 2' O METHYLADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; FATTY ACID; PHOSPHOLIPID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG SCREENING; FATTY ACID BLOOD LEVEL; FEMALE; HYPERTENSION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOSPHOLIPID BLOOD LEVEL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

ADENOSINE; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; HEART RATE; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; LIPIDS; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, PURINERGIC P1; STREPTOZOCIN;

EID: 0031959170     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(97)00116-2     Document Type: Article

References (23)

1. Olsson R.A., Pearson J.D. Cardiovascular purinoceptors. Physiol. Rev. 70:1990;761-845.
2. Foley J.E. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care. 15:1992;773-784.
3. Jackson E.K. Adenosine: a physiological brake on renin release. Ann. Rev. Pharmacol. Toxicol. 31:1991;1-15.
4. Bell P.A., Deems R.O., Evans J.L., Honer C.M., Young D.A. Effects of WAG994 on lipid and glucose metabolism in vitro and in vivo. Diabetes. 43(Suppl 1):1994;44A.
5. Banauch D., Bruemmer W., Ebeling W., Metz H., Rindfrey H., Lang H., Leybold K., Rick W. A glucose dehydrogenase for the determination of glucose concentrations in body fluids. Clin. Chem. Clin. Biochem. 13:1975;101-107.
6. Shimizu S., Tani Y., Yamada H., Tabata M., Murachi T. Enzymatic determination of serum-free fatty acids: a colorimetric method. Anal. Biochem. 107:1980;193-198.
7. Spayd R.W., Brusch B., Burdick B.A., Dappen G.M., Eikenberry J.N., Esders T.W., Figuras J., Goodhue C.T., LaRossa D.D., Nelson R.W., Rand R.N., Wu T.-W. Multilayer film elements for clinical analysis: applications to representative chemical determinations. Clin. Chem. 24:1978;1343-1350.
8. Takayama M., Itoh S., Nagasaki T., Tanimizu I. A new enzymatic method for determination of serum choline-containing phospholipids. Clin. Chim. Acta. 79:1977;93-98.
9. Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin. Chem. 19:1973;1350-1356.
10. Lopes-Virella M.F., Stone P., Ellis S., Colwell J.A. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin. Chem. 23:1977;882-884.
11. Tuck M.L., Corry D.B. Pathophysiology and management of hypertension in diabetes. Annu. Rev. Med. 42:1991;533-548.
12. De Fronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for DM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14:1991;173-194.
13. Anderson E.A., Mark A.L. The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Hypertension. 21:1993;136-141.
14. Iwase M., Nunoi K., Kikochi M., Maki Y., Kodama T., Sadoshima S., Fujishima M. Morphometrical and biochemical differences of endocrine pancreata between spontaneously hypertensive and normotensive rats with or without neonatal streptozotocin-induced diabetes. Lab. Invest. 60:1989;102-105.
15. 1 receptor agonist. Drug Dev. Res. 34:1995;276-288.
16. Belardinelli L., Giles W.R., West A. Ionic mechanisms of adenosine actions in pacemaker cells from rabbit heart. J. Physiol. 405:1988;615-633.
17. Webb R.L., McNeal R.B., Barclay B.W., Yasay G.D. Hemodynamic effects of adenosine agonist in the conscious spontaneously hypertensive rat. J. Pharmacol. Exp. Ther. 254:1990;1090-1099.
18. Collis M.G., Hourani S.M.O. Adenosine receptor subtypes. Trends Pharmacol. Sci. 14:1993;360-366.
19. Strong P., Anderson R., Coates J., Ellis F., Evans B., Gurden M.F., Johnstone J., Kennedy I., Martin D.P. Suppression of non-esterified fatty acids and triglycerides in experimental animals by the adenosine analogue GR 79236. Clin. Sci. 84:1993;663-669.
20. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
21. Reaven G.M., Chang H., Ho H., Jeng C.Y., Hoffman B.B. Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am. J. Physiol. 254:1988;E23-E30.
22. Endo A., Tsujita Y., Kuroda M., Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim. Biophys. Acta. 575:1979;266-276.
23. Tsujita Y., Kuroda M., Shimada Y., Tanzawa K., Arai M., Kaneko I., Tanaka M., Masuda H., Tarumi C., Watanabe Y., Fujii S. CS-514, a competitive inhibitor of 3-hydroxy-3-metylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta. 877:1986;50-60.